These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15916838)

  • 41. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Local immune responses following nasal delivery of an adjuvanted influenza vaccine.
    Scheerlinck JP; Gekas S; Yen HH; Edwards S; Pearse M; Coulter A; Sutton P
    Vaccine; 2006 May; 24(18):3929-36. PubMed ID: 16540213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is there a benefit from an early booster vaccination in the control of equine influenza?
    Heldens JG; van Loon AA; van de Zande S
    Vet J; 2007 Nov; 174(3):592-8. PubMed ID: 17560150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
    Holvast A; Huckriede A; Wilschut J; Horst G; De Vries JJ; Benne CA; Kallenberg CG; Bijl M
    Ann Rheum Dis; 2006 Jul; 65(7):913-8. PubMed ID: 16322083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
    Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
    J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secretory immune response after nasal vaccination with live attenuated influenza viruses.
    Crifö S; Vella S; Filiaci F; Resta S; Rocchi G
    Rhinology; 1980 Jun; 18(2):87-92. PubMed ID: 7403787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
    Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine.
    Kmiecik T; Arnoux S; Kobryn A; Gorski P
    J Asthma; 2007 Dec; 44(10):817-22. PubMed ID: 18097856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nasoflu - a live influenza vaccine.
    Drug Ther Bull; 1976 Jan; 14(1):3-4. PubMed ID: 1245145
    [No Abstract]   [Full Text] [Related]  

  • 52. Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors.
    Bektas O; Karadeniz C; Oguz A; Berberoglu S; Yilmaz N; Citak C
    Pediatr Blood Cancer; 2007 Dec; 49(7):914-7. PubMed ID: 17262793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
    J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
    Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serological response to vaccination against avian influenza in zoo-birds using an inactivated H5N9 vaccine.
    Bertelsen MF; Klausen J; Holm E; Grøndahl C; Jørgensen PH
    Vaccine; 2007 May; 25(22):4345-9. PubMed ID: 17467857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.